<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intravenous (IV) <z:chebi fb="0" ids="23359">colchicine</z:chebi> is occasionally prescribed for the treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001997'>gouty arthritis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The Food and Drug Administration (FDA) recently received a report of <z:hpo ids='HP_0011420'>death</z:hpo> in a patient that was associated with inappropriate IV dosing of <z:chebi fb="0" ids="23359">colchicine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>This report prompted further investigation of other <z:hpo ids='HP_0011420'>deaths</z:hpo> associated with IV <z:chebi fb="0" ids="23359">colchicine</z:chebi> use in the FDA Adverse Event Reporting System (AERS) and the medical literature </plain></SENT>
<SENT sid="3" pm="."><plain>A total of 20 <z:hpo ids='HP_0011420'>deaths</z:hpo> were identified </plain></SENT>
<SENT sid="4" pm="."><plain>Eight patients were females, 11 were males, and the gender was unknown in 1 </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> cases, the recommended maximum cumulative dose of 2 to 4 mg during a course of therapy was exceeded </plain></SENT>
<SENT sid="6" pm="."><plain>Dose reductions are recommended in patients with renal or <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">hepatic disease</z:e> and in the elderly </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> reported adverse events were associated with <z:chebi fb="0" ids="23359">colchicine</z:chebi> toxicity, including <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, <z:hpo ids='HP_0001882'>leukopenia</z:hpo>, <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>, <z:mp ids='MP_0000334'>agranulocytosis</z:mp>, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, <z:hpo ids='HP_0001919'>acute renal failure</z:hpo>, and disseminated intravascular <z:hpo ids='HP_0003256'>coagulopathy</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0011420'>Death</z:hpo> occurred within 1 to 40 days after drug administration </plain></SENT>
<SENT sid="9" pm="."><plain>Therapeutic guidelines exist for use of IV <z:chebi fb="0" ids="23359">colchicine</z:chebi> and these guidelines should be followed to prevent serious toxicities and <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
</text></document>